David Gryska

David Gryska has over 35 years of experience as a senior financial executive at life science and biotechnology companies. Mr. Gryska has been involved in over $20 billion in Biotech financings and M&A transactions during his career. He has served as Executive Vice President and Chief Financial Officer of Incyte Corporation, and he served as Senior Vice President and Chief Financial Officer of Celgene Corporation. Previously, Mr. Gryska served as Senior Vice President and Chief Financial Officer at Scios, Inc. Scios was acquired by Johnson & Johnson. He also served as Vice President, Finance and Chief Financial Officer at Cardiac Pathways, a medical device company later acquired by Boston Scientific Corporation. Prior to Cardiac Pathways, Mr. Gryska served as a partner at Ernst & Young, an accounting firm in California.

Mr. Gryska holds a B.A. in Accounting and Finance from Loyola University and an M.B.A. from Golden Gate University. He currently serves on the Board of Directors of two public biotechnology companies. In the past 20 years, Mr. Gryska has served on the Boards of six other public biotechnology companies. He was on the Board of Seagen for over 15 years which was acquired by Pfizer for over $44 billion in 2023.